InvestorsHub Logo
Followers 216
Posts 11783
Boards Moderated 3
Alias Born 01/20/2012

Re: None

Tuesday, 02/07/2012 9:44:20 AM

Tuesday, February 07, 2012 9:44:20 AM

Post# of 167
~ AMLN~ Jefferies believes Amylin's 2012 guidance suggests upside to its Exenatide sales estimates. The firm upped its price target for shares post the company's Q4 results and keeps a Buy rating on the stock. Up $1.13